| 结核病免疫治疗的研究进展 |
| |
| 引用本文： | 王丽,杨恩卓,沙巍,沈洪波. 结核病免疫治疗的研究进展[J]. 中国防痨杂志, 2022, 44(10): 1079-1084. DOI: 10.19982/j.issn.1000-6621.20220194 |
| |
| 作者姓名： | 王丽 杨恩卓 沙巍 沈洪波 |
| |
| 作者单位： | 同济大学附属上海市肺科医院结核病临床研究中心,上海 200433 |
| |
| 基金项目： | 国家自然科学基金(31970876);国家自然科学基金(32070943);上海市感染性疾病(结核病学)临床医学研究中心(19MC1910800);上海市科学技术委员会重大研究项目(20Z11900500) |
| |
| 摘 要： | 目前结核病临床治疗面临众多挑战，特别是耐多药结核病。免疫治疗可以提高机体对结核分枝杆菌感染的保护性免疫应答，是常规化学药物治疗的重要辅助。本文总结了有潜力用于结核病免疫治疗的细胞因子、免疫细胞以及免疫调节药物的研究进展，并分析了其临床应用前景，旨在为结核病的临床研究和机制探索提供思路。
|
| 关 键 词： | 结核 免疫 综述文献(主题) |
| 收稿时间： | 2022-05-23 |
Research progress in immunotherapy of tuberculosis |
| |
| Wang Li,Yang Enzhuo,Sha Wei,Shen Hongbo. Research progress in immunotherapy of tuberculosis[J]. The Journal of The Chinese Antituberculosis Association, 2022, 44(10): 1079-1084. DOI: 10.19982/j.issn.1000-6621.20220194 |
| |
| Authors: | Wang Li Yang Enzhuo Sha Wei Shen Hongbo |
| |
| Affiliation: | Clinical Research Center of Tuberculosis,Shanghai Pulmonary Hospital,Tongji University,Shanghai 200433,China |
| |
| Abstract: | At present, the treatment of tuberculosis, especially multidrug-resistant tuberculosis (MDR-TB) faces many challenges. Immunotherapy can improve the protective immunological response to Mycobacterium tuberculosis infection, thus is an important beneficial supplement to conventional chemotherapy. In this paper, we summarize the research progress of cytokines, immunological cells and immunomodulatory drugs that have the potential to be used in the immunotherapy of tuberculosis and analyze their clinical application prospects, to provide ideas for future clinical researches and mechanism exploration of tuberculosis. |
| |
| Keywords: | Tuberculosis Immunity Review literature as topic |
|
| 点击此处可从《中国防痨杂志》浏览原始摘要信息 |
|
点击此处可从《中国防痨杂志》下载全文 |
